ライフサイエンスコーパス: new drug

1 d against virus known to be resistant to the new drug.

2 subsequent steps involved in discovery of a new drug.

3 riteria governing regulatory approval of any new drug.

4 dard 3-drug combination with the addition of new drugs.

5 r to identify new drug targets and to design new drugs.

6 validated strategy toward the development of new drugs.

7 These mechanisms make attractive targets for new drugs.

8 sis represents a global emergency, requiring new drugs.

9 ir targets is crucial for the development of new drugs.

10 shorter timelines than developing completely new drugs.

11 c changes is critical for the development of new drugs.

12 rises regardless of the nature or potency of new drugs.

13 edications; and 2 studies on all marketed or new drugs.

14 y WHO as a global priority for investment in new drugs.

15 innovative human platform for the testing of new drugs.

16 are of high interest for the development of new drugs.

17 he bio-medical research and the discovery of new drugs.

18 as a major health issue fuelling demand for new drugs.

19 out dosing information as the only access to new drugs.

20 and specificity for the tests performed with new drugs.

21 ammes aimed at facilitating faster access to new drugs.

22 ake predictions for both new tumor cells and new drugs.

23 transplantation forms the basis for testing new drugs.

24 up access to life saving DR-TB regimens with new drugs.

25 drugs and predict the analgesic efficacy of new drugs.

26 to ACT highlights the importance of finding new drugs.

27 assessment of the proarrhythmic potential of new drugs.

28 riatic treatment, an area with high need for new drugs.

29 ew personnel responsible for the approval of new drugs.

30 promising candidates for the development of new drugs.

31 r these agents, hampering the development of new drugs.

32 Of these, 65% are investigational new drugs, 17% are new drug applications and 18% are abb

33 ns (1962-2018) and FDA databases of approved new drugs (1984-2018), generic drugs (1970-2018), biolog

34 nd other CDNs, including the investigational new drug 2'3'-bisphosphosphothioate-cyclic-di-AMP (2'3'-

35 Beyond continued research and development of new drugs, a focus on drug repurposing could alleviate t

36 ation of TPC1 might blaze a trail to develop new drugs against mast cell-related diseases, including

37 New drugs against STNs are urgently needed.

38 ategy for drug repositioning, and identified new drugs against the VCP/p97/ERAD pathway in human dise

39 There is an urgent need to develop new drugs against tuberculosis.

40 st cells is highly relevant to the design of new drugs aimed at eliminating HIV-1 from infected indiv

41 This work has implications for both the new drug and the antibodies that are poised to be used a

42 more frequent, requiring the development of new drugs and a better understanding of the targeted enz

43 th novel perspectives for the development of new drugs and active targeting in glioblastoma multiform

44 cription drug user fee funding expanded from new drugs and biologics in 1992 to generic and biosimila

45 The FDA approved 355 new drugs and biologics over the study period.

46 Therefore, during the assessment of new drugs and candidate compounds, ROS generation is an

47 nd now threaten to stifle the development of new drugs and devices.

48 tal-based therapeutics and holds promise for new drugs and drug delivery designs.

49 drugs, the interval between registration of new drugs and first data on pharmacokinetics and safety

50 n the use of antiretroviral drugs, including new drugs and formulations, for the treatment and preven

51 y are marketed, with safer or more effective new drugs and greater marketing associated with higher i

52 ts for testing the safety and/or efficacy of new drugs and of new medical devices.

53 Finally, we discuss the need for new drugs and outline promising targets for future thera

54 bsets of pain, evaluate target engagement of new drugs and predict the analgesic efficacy of new drug

55 ed with disease progression, and identifying new drugs and routes of administration as well as new, s

56 Despite the therapeutic potential of new drugs and small molecules, there remains a gap in th

57 New drugs and targets are being investigated to cope wit

58 This has generally necessitated a switch to new drugs and the discontinuation of older ones, after w

59 d in 2019 that has led to the development of new drugs and therapeutic regimens, vaccine candidates,

60 ZIKV infection may be useful for testing of new drugs and vaccines.

61 mation is provided to facilitate abbreviated new drug application (ANDA) submission.

62 This study investigated New Drug Application (NDA) labeling documents for 1164 s

63 rs of the Food and Drug Administration (FDA) new-drug application (NDA) process that ultimately resul

64 Abbreviated New Drug Applications (ANDA) data that included manufact

65 t a longitudinal analysis of investigational new drug applications (INDs) for new, systemic antibacte

66 On December 1, 2020, 2 separate new drug applications (NDAs) submitted by each instituti

67 , 65% are investigational new drugs, 17% are new drug applications and 18% are abbreviated new drug a

68 a series of teleconferences; a review of 46 New Drug Applications from registration studies of uniqu

69 Food and Drug Administration (FDA) through new drug applications, and none of them have generic cou

70 ew drug applications and 18% are abbreviated new drug applications, with the largest class of product

71 The success rates for new drug approvals in the United States are < 15%, and i

72 The mean annual number of new drug approvals, including biologics, was 34 from 199

73 Monitoring of regulatory agencies for new drugs approvals ensures the resource is up-to-date.

74 e-threatening disease in many countries, and new drugs are clearly needed.

75 New drugs are crucially needed for children with cancer.

76 New drugs are desperately needed to combat methicillin-r

77 to widespread resistance to these therapies, new drugs are desperately needed to control the TB disea

78 udy to date, results of BPDCN trials testing new drugs are difficult to compare with alternative ther

79 previous analysis, approximately 70% of all new drugs are made up of only ring systems that have bee

80 New drugs are needed for leishmaniasis because current t

81 roduction of platinum-based chemotherapy and new drugs are needed.

82 tional approaches for the rapid discovery of new drugs are needed.

83 on modification of NAFLD risk factors, many new drugs are now in clinical trials, including trials s

84 an inform clinical and policy discussions of new drugs as they enter the market.

85 ance and is able to predict gene targets for new drugs as well as drugs that potentially target unexp

86 derable complexity to the rational design of new drugs, as it involves the optimization of multiple b

87 Conducted under an investigational new drug authorization, we prospectively enrolled patien

88 raction might be exploited for the design of new drugs based on the nicotine scaffold.

89 l compounds could lead to the development of new drugs based on the use of natural ingredients.

90 an expanded-access emergency investigational new drug basis.

91 ing as a promising target for development of new drugs because it appears possible to inhibit growth

92 US law requires testing of new drugs before approval to ensure that they provide a

93 check an individual's response to potential new drugs before clinical trials.

94 erstand overall treatment effectiveness of a new drug being tested.

95 has increased over time, with 81% (48/59) of new drugs benefiting from at least 1 such expedited prog

96 Alternative strategies with new drugs, both antiplatelet and anticoagulant agents, a

97 he bulk of its efforts on the development of new drugs, but an alternative approach is to improve the

98 compounds are central to the development of new drugs, but preparing them can be challenging because

99 Here, we have tested a potent new drug called imipramine blue (IB), which is a chimeri

100 m to overcome current treatment limitations, new drugs can be developed by specifically modulating, t

101 y cholangitis and PSC in the hope that these new drugs can be used more effectively.

102 the antimalarial activity of artefenomel, a new drug candidate.

103 aving the way for testing its potential as a new drug candidate.

104 ession signatures yielded leads for possible new drug candidates and natural compounds upon bioinform

105 Several new drug candidates have been generated and are currentl

106 current antimalarial drugs, the discovery of new drug candidates is a major global health priority.

107 enefits and minimizing risks associated with new drug candidates on given populations.

108 posing analyses, yielding leads for possible new drug candidates such as SC-560 (an NSAID), and amoxa

109 of OCT1/2 and MATEs in clinical studies with new drug candidates.

110 e limited efficacy, prompting the search for new drug candidates.

111 oughput chemical screening in the search for new drug candidates.

112 tant consideration for the likely success of new drug candidates.

113 and suggesting a novel screen for safety of new drug candidates.

114 y study aims to evaluate foam as a potential new drug carrier for IPC delivery.

115 man disease processes, we have implemented a new drug class and have used it initially to annotate dr

116 ucose cotransporter 2 inhibitors (SGLT2i), a new drug class approved for treatment of diabetes, have

117 Here, pioneers of this new drug class provide a bench-to-bedside review on prec

118 f 'migrastatics' allows the development of a new drug class that is neither cytotoxic nor antiprolife

119 icant public health concern, and the lack of new drug classes for these pathogens is linked to the in

120 in surgical practice and the development of new drug classes to improve the function and longevity o

121 lity criteria for commercial investigational new drug clinical trial applications submitted to the US

122 ward genetic screening method in identifying new drug combinations to combat acquired BRAFi resistanc

123 d to improved efficacy in clinical trials of new drug combinations, thereby increasing the survival o

124 has immediate significance for the design of new drug combinations.

125 ommon therapeutic strategy in oncology, with new drugs continuously in development.

126 by a paucity of preclinical models in which new drugs could be tested for target engagement and anti

127 e to a lack of economic incentive to develop new drugs, current treatments have severe limitations in

128 Two new drugs, delamanid and bedaquiline, have recently been

129 New drug delivery systems are highly needed in research

130 In addition, new drug delivery systems, such as implants and transder

131 s a valuable strategy for the development of new drug delivery systems.

132 Mito-XGBoost also plays an important role in new drug design for the treatment of related diseases.

133 zed as one of the most important targets for new drug design in cancer, cardiovascular, and neurologi

134 ovides an effective pre-filtering method for new drug design.

135 BV RNA transcription from cccDNA, and assist new drug development and disease management.

136 Last, we discuss new drug development approaches for pediatric cancers wh

137 The lack of new drug development in kidney transplantation necessita

138 elerate the evaluation and prioritization of new drug development programmes and repurposing of trial

139 ivity, while serving to incentivize targeted new drug development, have exacerbated inequitable outco

140 ng drug repurposing, precision oncology, and new drug development, through different data partition s

141 the lysosome as an underexplored target for new drug development.

142 on rates, substantial costs and slow pace of new drug discovery and development, repurposing of 'old'

143 g and future pathway research may help focus new drug discovery efforts on key novel targets and mech

144 A new drug discovery method based on drug response, which

145 ified HX, GSN and AAT as potential leads for new drug discovery programs.

146 uation With OFDI of Strut Coverage of Terumo New Drug Eluting Stent With Biodegradable Polymer at 1,

147 e to better understand the interplay between new drug entry and intraclass drug prices.

148 It is a noninvasive tool to screen new drugs, evaluate toxicants, and elucidate disease mec

149 Many promising new drugs fail in the early stages of clinical trials.

150 This Ab could serve as a potential new drug for aHUS patients and alternative to C5 blockad

151 BT-11 is an investigational new drug for IBD that is orally active, gut restricted,

152 compound 1 deserves attention as a potential new drug for triple-negative breast cancer therapy.

153 Bedaquiline (BDQ) is the first new drug for tuberculosis (TB) approved in more than 40

154 g allergic reactions, representing potential new drugs for allergies.

155 int enzymes in metabolic pathways has led to new drugs for cancers, autoimmune disorders and infectio

156 questions in lung biology and for developing new drugs for disorders such as cystic fibrosis and asth

157 Rationale: Several new drugs for idiopathic pulmonary fibrosis (IPF) are in

158 (nNOS) inhibitors toward the development of new drugs for neurodegenerative diseases.

159 New drugs for the treatment of malaria and cryptosporidi

160 e efforts in medicinal chemistry to discover new drugs for this devastating disease.

161 st response, should lead to the discovery of new drugs for treating infections.

162 bA) and its precursor mini-MbA are potential new drugs for treating type 2 diabetes.

163 death has not decreased with development of new drugs for treatment of IBD.

164 8 by the US Food and Drug Administration for new drugs for type 2 diabetes mellitus, many large rando

165 tus, requiring no additional measurements or new drug formulations, is one approach to improve tuberc

166 manner, but also to deliver within the cells new drug-free therapeutic effects by using pure physical

167 The mean cost of developing a new drug has been the subject of debate, with recent est

168 pproval, Fast-Track, and Priority Review for new drugs has increased over time, with 81% (48/59) of n

169 last In the Clinic on SIHD in 2014, several new drugs have been approved to reduce ischemic complica

170 ost immunity towards tumor killing, and many new drugs have been developed to target this interaction

171 Fewer than half of new drugs have data on their comparative benefits and ha

172 An increasing number of new drugs have their origin in small biotech or academia

173 op organized by the Stop TB Working Group on New Drugs, held at the Gordon Research Conference for Tu

174 type of antibody worked really well with the new drug in blocking virus infection of cells.

175 es or compound libraries have not produced a new drug in over 30 years.

176 omics is valuable in identifying targets for new drugs in different human diseases including bacteria

177 osing - evaluate subtherapeutic exposures of new drugs in first-in-human studies known as exploratory

178 d test was established to give developers of new drugs in the preclinical stage the opportunity to te

179 be used as a control arm in future trials of new drugs in this setting.

180 issues faced by hematologists in this era of new drugs include (1) the timely identification of actio

181 n both adults and paediatric population with new drugs included as culprit.

182 New drugs including N-acetylcysteine, bortezomib, recomb

183 Currently, investigational new drug (IND)-enabling studies with 1 are underway.

184 900), the National Major Projects for "Major New Drugs Innovation and Development" (Grant No.2018ZX09

185 Crucially this highlights how new drugs, introduced to circumvent known resistance mec

186 This quintet of new drugs is likely to reshape the therapeutic landscape

187 In the search for new drug-like selective G-quadruplex binders, a bioinspi

188 The spiraling cost of new drugs mandates a fundamentally different approach to

189 In the endTB (expand new drug markets for TB) Observational Study, which enro

190 The most common therapeutic needs involved new drugs (n = 149, 51.0%), cell regeneration (n = 115,

191 ife solutes is proposed, taking cubosomes as new drug nanocarriers of potential interest for drug del

192 To aid in the development of new drug nanocarriers, we propose a novel plasmonic nano

193 New drugs or combinations are needed to improve patient

194 During the development of new drugs or compounds there is a requirement for precli

195 peptides have drawn significant attention as new drugs or drug adjuvants to combat multidrug-resistan

196 dification of existing drugs, development of new drugs, or combination of novel drug delivery agents

197 ng enzymes can complicate the development of new drugs, owing to the potential to cause drug-drug int

198 perimentally measured the interaction of 123 new drug pairs, as a prospective validation set for our

199 Food and Drug Administration investigational new drug pathway.

200 that such competition may help restrain how new drug prices are set.

201 ment of new pharmaceutical technologies, and new drug products leading to continuous manufacturing pr

202 BAT under an expanded-access Investigational New Drug program.

203 viral drugs worldwide and anticipated use of new drugs, prospective follow-up of pregnant women and b

204 viral drugs worldwide and anticipated use of new drugs, prospective follow-up of pregnant women and b

205 design of green catalysts and the pursuit of new drug regimens.

206 There were no new drug-related safety signals.

207 plained clinical observations and suggesting new drug repositioning opportunities.

208 bal threat, which besides the development of new drugs, requires rapid, cheap, scalable, and accurate

209 ith fewer long-term liabilities, efficacy on new drug-resistant HIV-1 strains, and less frequent dosi

210 menced treatment for around 17% of estimated new drug-resistant patients.

211 line cannot be used for studies of TANDs or new drug screening.

212 ystem, identified about 58% of the estimated new drug-sensitive (DS) TB patients in 2016.

213 gocytic cup formation and might constitute a new drug target for amoebic dysentery.

214 Hence, T-channels may be a promising new drug target for different cognitive deficits.

215 Our study identifies Vps34 as a new drug target for insulin resistance in Type-2 diabete

216 Brachyury is emerging as an exciting new drug target for the rare bone cancer chordoma.

217 t-sensing receptor and represents a possible new drug target in metabolic disorders.

218 membrane remodeling will help to identify a new drug target in the fight against the increased antib

219 enome suggesting that it could be a putative new drug target with similar utility as that of the mala

220 in the N-terminal region of NHR trimer as a new drug target, and then we designed several short arti

221 . brucei could potentially be exploited as a new drug target.

222 grating heterogeneous information to predict new drug-target interactions and repurpose existing drug

223 ult, computational methods for predictioning new drug-target interactions have gained a tremendous in

224 Prediction of new drug-target interactions is critically important as

225 and (4) building DNILMF model and smoothing new drug/target predictions based on their neighbors.

226 cedure consists of four steps: (1) inferring new drug/target profiles and constructing profile kernel

227 We here present a new drug targeting approach that combines both drug clas

228 n this article, we review efforts to develop new drugs targeting these processes, including agents th

229 entified that may be useful in the design of new drugs targeting these receptors.

230 presents the ideal attributes of a promising new drug, targeting specific tissues based on chemotacti

231 m widespread resistance, creating a need for new drug targets against influenza virus.

232 ted disease mechanisms, to predict potential new drug targets and anti-metabolites, and to identify b

233 Identifying new drug targets and developing safe and effective drugs

234 l challenges have intensified the search for new drug targets and drugs that can benefit patients who

235 eishmanial drugs advocates identification of new drug targets and their inhibitors for visceral leish

236 ly needed as more relevant tools to identify new drug targets and therapies.

237 al models of disease progression, and reveal new drug targets and therapies.

238 tions confer resistance in order to identify new drug targets and to design new drugs.

239 sms of epileptogenesis and identification of new drug targets can be transformative.

240 ecome the major bottleneck in the search for new drug targets for AD.

241 al biology in PD risk, and suggest potential new drug targets for PD.

242 lasmic gelsolin signaling pathway, providing new drug targets for the treatment of demyelination dise

243 ERD and related traits and uncover potential new drug targets for these conditions.

244 tissue function to promote identification of new drug targets for treating obesity and related metabo

245 nels in lung function and their potential as new drug targets in the treatment of pulmonary hypertens

246 Uncovering new drug targets that simultaneously reduce both Abeta p

247 o novel biomarkers and hopefully a series of new drug targets to tackle this disease.

248 L1-interacting molecules that could serve as new drug targets to treat APOL1-associated renal disease

249 anscriptional regulators and have emerged as new drug targets, but their functional distinction has r

250 BD need to be discovered that can be used as new drug targets.

251 ntered during infection in order to identify new drug targets.

252 olecular tools has hindered the discovery of new drug targets.

253 activation and ALS, which may help discover new drug targets.

254 esis represents a useful strategy to uncover new drug targets.

255 subgroups and lead to the identification of new drug targets.

256 the genetic architecture of SCZ and provides new drug targets.

257 New drugs that control tumor growth and favorably modula

258 effective drugs, and to continue to develop new drugs that do not cause these side-effects and have

259 Thus, new drugs that inhibit RNR are needed to be developed.

260 he clinical management of TMJ OA by defining new drugs that target angiogenesis or block the cartilag

261 New drugs that target Plasmodium species, the causative

262 Furthermore, for new drugs, the AUC value of DDIGIP in de novo drug valid

263 For the development of new drugs, the investigation of their metabolism is of c

264 tance emphasizes the need for optimal use of new drugs, the need for drug resistance surveillance, an

265 for investigating complex human diseases and new drug therapies because of their shared genetics and

266 transplantation, and discoveries of putative new drugs through systematic drug screening using large

267 e benzimidazole inhibitor might be used as a new drug to block the recruitment of immune cells during

268 e multidisciplinary effort needed to bring a new drug to clinical trial.

269 d egress offer hope for a desperately needed new drug to combat this nefarious organism.

270 search and development investment to bring a new drug to market was estimated at $985.3 million (95%

271 USD, development cycle for bringing a single new drug to market.

272 optosis may contribute to the development of new drug to treat lymphomas and oncovirus infections.

273 ed chemicals for clinical trials and develop new drugs to combat cancer and other diseases.

274 obal health emergency and there is a lack of new drugs to control MDR pathogens.

275 These small molecules represent potential new drugs to help maintain P(i) homeostasis in patients

276 athogenesis and aid in the identification of new drugs to improve the treatment of these serious infe

277 hanisms of multimorbidities, introduction of new drugs to the clinics, recently completed phase three

278 the approval of delamanid and pretomanid as new drugs to treat drug-resistant tuberculosis, there is

279 d the etiology of human diseases and develop new drugs to treat them.

280 There is an urgent need for new drugs to treat VL, because current therapies are unf

281 tly increased only in the presence of recent new drug treatment with antiepileptics or allopurinol, r

282 SJS/TEN mostly manifest as a reaction to new drug use, but little is known about their incidence

283 that an accelerated approval of a particular new drug using an intermediate end point, such as MRD, w

284 initial relational score in the presence of new drugs via the chemical, biological, phenotypic data

285 In a large clinical trial, this new drug was found to reduce hospitalization and mortali

286 wo types of anabolic agents (including three new drugs), which represent a novel approach to improvin

287 dynamics can be a powerful tool in designing new drugs with engineered binding/unbinding kinetics.

288 rgoing a renaissance with the expectation of new drugs with enhanced levels of efficacy and safety.

289 ight also be suitable for the development of new drugs with improved performance.

290 his cost-benefit analysis, we identified all new drugs with initial indications for adult cancers tha

291 iotic resistance requires the development of new drugs with novel antibacterial targets.

292 New drugs with novel chemical structures are needed to o

293 Even with the success of HAART, new drugs with novel mechanisms are needed to combat vir

294 New drugs with novel mechanisms of action, such as cardi

295 only be resolved through the development of new drugs with novel mechanisms of action.

296 (XDR-TB) cases, there is an urgent need for new drugs with novel mechanisms of action.

297 lciparum and underscores the urgent need for new drugs with novel modes of action.

298 The discovery of new drugs with novel targets is paramount to the continu

299 s (PDO) serve as promising tools to identify new drugs with therapeutic potential in PDAC.

300 The incorporation of such new drugs within a CHOP backbone is under investigation